AI in Healthcare and Life Sciences
Applied AI in medicine, biology, drug discovery, diagnostics, clinical workflows, research labs, and healthcare administration.
Scientific Capacity Has Outpaced the Systems That Turn Discoveries Into Cures
Science communicator Saloni Dattani argues that medicine has made substantial, often incremental gains—from steep declines in heart-disease deaths to new vaccines and cancer treatments—but scientific capability alone does not produce cures. In her TED talk, she says treatments are delayed when markets do not reward development, trials cannot recruit enough patients, or research is poorly matched to how diseases spread. Malaria, childhood leukemia and Ebola show how targeted funding, cross-border trial networks and adaptive study designs can turn existing knowledge into lifesaving care.
Assetlessness Is Driving America Toward State Dependence
David Friedberg, entrepreneur, scientist and member of President Trump’s science advisory council, argues that America’s drift toward socialism reflects an ownership crisis rather than an ideological conversion. As housing, healthcare, education and retirement become less attainable for people living on wages, he says, voters will increasingly seek state guarantees. Friedberg’s alternative is to help more Americans move from labor to capital—while ensuring they share in AI-driven growth—but Steven Bartlett questions whether that transition can happen quickly enough for workers displaced along the way.
MHS Gives AI Agents a Common Interface for Lab Equipment
Anthropic and HHMI Janelia Research Campus are proposing the Model Hardware Standard as a common interface for AI agents to operate laboratory and manufacturing equipment, replacing custom software links between individual devices. Alek Kemeny and Arco Bast argue that giving instruments a shared connection layer lets agents execute and recover experiments, coordinate microscope work, and shorten the time required to test scientific hypotheses.
Postpartum Depression May Reflect the Collapse of Shared Childcare
Psychologist Darby Saxbe argues that postpartum depression may reflect a mismatch between humans’ cooperative caregiving history and the isolation imposed on many modern parents. She says new mothers and fathers need more than encouragement: paid leave, a participating partner, time to recover, and a social network in which others take responsibility for specific childcare and household tasks. Saxbe points to evidence linking paternity leave and practical support with better maternal mental-health outcomes.
Partial Reprogramming Aims to Reverse Aging Without Erasing Cell Identity
Harvard geneticist David Sinclair argues that aging is partly a loss of cellular information that could be restored through partial epigenetic reprogramming. He says his lab’s first human trial, in the eye, is testing whether a three-gene approach can improve vision without erasing cell identity or triggering cancer; broader claims about whole-body rejuvenation remain based on animal and unpublished work. Until such therapies arrive, Sinclair’s prescription is conventional: protect health through weight, exercise, sleep, diet and risk-specific medical care.
Patient Price Visibility and Provider Competition Could Lower Healthcare Costs
Scott W. Atlas argues that American healthcare’s high costs and uneven access stem less from insufficient coverage than from a system that shields patients from prices and limits competition among providers. He favors consumer-directed insurance and health savings accounts, transparent pricing for scheduled care, and fewer restrictions on physician training, licensing, and nonphysician practice. Atlas also contends that Medicaid enrollment does not ensure access, while drug-price controls risk weakening the incentives for pharmaceutical innovation.
Restoring Sensory Pathways Is the Central Goal of Neural Interfaces
Science.xyz co-founder and CEO Max Hodak argues that neural interfaces should be judged less by the BCI label than by whether they can restore the sensory and motor pathways through which the brain receives and acts on the world. He presents Science’s PRIMA retinal implant, which has European marketing approval, as an early proof: it bypasses damaged photoreceptors to give some blind patients form vision rather than ordinary sight. Hodak’s broader case is that treating the brain as a computational system could lead to devices that repair lost capabilities while offering a new way to study intelligence.
Sinclair’s Two-Week Fast Relies on Supplements, Monitoring and Exercise
David Sinclair describes his two-week fasts as a monitored, supplement-supported personal practice, not a water-only regimen or general advice, while his broader case for eating less often rests chiefly on animal evidence. He says that after roughly three days without conventional meals, his hunger recedes and he feels clearer, less bloated and more energized.
Robeauté Targets 2027 Human Trials for Brain Microrobot
Robeauté is developing rice-sized microrobots that it says could navigate through brain tissue to collect biopsies or deliver therapies directly to hard-to-reach sites. Chief executive Joana Cartocci argues that advances in drugs, gene therapies and AI will remain limited unless they can be placed precisely in the brain, bypassing obstacles such as the blood-brain barrier. The French startup plans to begin with advanced tumor biopsy in first-in-human studies targeted for 2027, before expanding to other uses.
Rapid Ketamine Relief Points to Brain Plasticity in Depression
Neuroscientist Lisa Monteggia argues that depression cannot be adequately explained as a serotonin shortage: SSRIs raise serotonin quickly, yet often take weeks to relieve symptoms, while ketamine can produce relief within hours through a different brain system. She says ketamine’s effects point instead to synaptic plasticity—the brain’s capacity to adapt—as a possible driver of antidepressant response, though the drug remains temporary, clinically limited and no replacement for first-line SSRI treatment.
The Best Diet Is Sustainable, Plant-Rich, and Minimally Processed
Harvard evolutionary biologist Daniel Lieberman argues that the search for a single “best” diet is misguided: dietary effects vary by person, goal and context, while the long-term evidence rarely permits certainty. His reading favors durable, plant-rich patterns built around minimally processed foods, fiber-rich carbohydrates and adequate protein over meat-heavy or highly restrictive regimens. The central challenge, he says, is not finding a perfect protocol but sustaining reasonable eating in an environment designed to promote overconsumption.
Most Sleep Apnea Cases Go Undiagnosed, Especially Among Women
Dr Andy Galpin, professor of kinesiology and executive director of Parker University’s Human Performance Center, argues that persistent poor sleep and fatigue should be treated first as possible medical problems, not failures of optimization. He says roughly a billion people may have sleep apnea and that most cases go undiagnosed, often because people without the stereotypical profile of loud snoring and larger body size mistake symptoms for stress, aging or insomnia. Trackers, supplements and sleep routines can help identify patterns, Galpin says, but they should not delay clinical assessment when a disorder is plausible.
Pixel 11 Raises Prices as Starting Memory Falls
Google’s Pixel 11 lineup raises entry prices while reducing starting memory, a shift the company attributes to a severe memory shortage, Bloomberg Senior Tech Editor Dana Wollman says. The phones add performance and durability upgrades and a HiLight notification feature that uses the rear flash, but retain a design Google has used for roughly three years. Google also introduced a wearable tool that estimates patterns associated with insulin resistance and directs users to consult a doctor rather than offering a diagnosis.
Hidden Workflows Become Businesses When Failure Has an Owner
Sam Parr and Shaan Puri argue that large businesses often sit behind visible services, handling recurring operational failures that customers already pay to manage. Their examples—from dental insurance claims and hospital generator maintenance to the supply of research animals for drug testing—share a structure: the cost of failure is clear, the buyer is identifiable, and a specialist can take responsibility for work customers do not want to run themselves. Puri’s advice is to get close enough to real workflows to notice where the formal process breaks down.
AI Has Shifted the Competitive Frontier for Software Incumbents
Benchmark general partner Eric Vishria argues that AI is moving the competitive frontier for software faster than incumbents can respond by adding features to existing roadmaps. In his view, companies can destroy value while executing a pre-AI plan because model capabilities are weakening old switching costs, changing what customers value, and demanding products built around AI’s uneven, rapidly shifting capabilities. Vishria also contends that the market can support major winners across models, infrastructure and applications, though power, deployment expertise and operational execution will determine who captures the value.
Antibiotic Stewardship Is Undermining the Economics of Drug Development
Antibiotics are indispensable medicines, but their commercial model is breaking down, argues the Financial Times’ Aanu Adeoye: they take decades and more than $1bn to develop, yet responsible use requires that sales be kept low. As drug resistance drives more than 1mn deaths a year and large companies cut their pipelines, advocates are pushing subscription payments that reward access rather than volume, alongside greater public funding for development.
OpenAI’s First Device Tests the Case for Personal AI Systems
The article argues that AI’s value may accrue less to models than to the products and compute systems that make their capabilities usable, while the costs of new technologies may be shifted onto the public. Coogan treats OpenAI’s reported device and Google’s infrastructure strategy as tests of that proposition; AI-designed bacteriophages raise a separate question of whether cheaper biological design can widen medical uses while creating biosecurity risks. The hosts also point to social-media litigation as a potential model for making platforms bear public costs attributed to product design.
Public Health Preparedness Must Address Pathogens, Markets, and Organized Distrust
Peter Hotez, dean of Baylor College of Medicine’s National School of Tropical Medicine, argues that public health is being weakened at every stage: climate and urbanization increase the chance of disease emergence, market failures leave vaccines without routes to the populations that need them, and organized political and commercial campaigns erode uptake where outbreaks can spread. His case for preparedness centers on earlier pathogen surveillance, vaccine production models built for low-income markets, and stronger institutional resistance to what he describes as a monetized anti-vaccine ecosystem.
Food Fortification Scales Only When Hardware Meets Enforcement
Felix Brooks-Church, co-founder of food-fortification enterprise Sanku, argues that “hidden hunger” can be addressed by adding essential nutrients to staple foods at the local mills that produce them. His model combines mill-compatible dosing machines, remote monitoring and local premix supply, but he says durable national scale ultimately depends on governments mandating fortification and enforcing standards through testing and inspection.
Clinical Support, Not Recreation, Changed Huberman’s View of Psychedelics
Stanford neuroscientist Andrew Huberman says his view of psychedelics changed not because he became an advocate, but because clinically supported sessions gave him access to psychological material he had not been able to reach through therapy, journaling, or the drugs separately. He argues that MDMA and psilocybin served different roles in that work—one making difficult emotions bearable, the other exposing patterns and absences—and that their value depended on trained guidance and follow-through in ordinary life.
Phasing Out Fossil Fuels Delivers Immediate Public-Health Benefits
Edward Maibach argues that phasing out fossil fuels should be treated as an immediate public-health intervention, not only a response to future climate risks. Alongside pediatrician Lisa Patel, sanitation advocate Catherine Coleman Flowers and air-quality entrepreneur Darren Riley, he points to local benefits—from fewer asthma exposures near schools and in homes to safer water during floods—that can make decarbonization a more concrete policy choice.
Peptide Hype Outruns Evidence, Dosing Knowledge, and Product Quality
Stanford neuroscientist Andrew Huberman argues that peptides should be judged by dose, evidence and sourcing rather than by their status as naturally occurring molecules. He distinguishes GLP-based weight-loss drugs, which he says have powerful effects and meaningful trade-offs, from growth-hormone secretagogues that can shift hormone measurements without delivering expected gains in strength or recovery. BPC-157, meanwhile, has promising animal data but no published human trial, he says, making gray-market use particularly difficult to justify.
Food as Medicine Depends on Farms, Kitchens, and Community
Food as medicine depends on more than getting healthier ingredients onto a plate, argues moderator Corby Kummer and a panel of Chicago chefs and food-system leaders: it requires affordable access, viable farms, cooking knowledge and time to turn food into meals. Rick Bayless cautions that treating food as medicine can strip it of pleasure, while Cliff Rome and Sarah Stegner describe teaching kitchens, markets and farmer-support programs as ways to make fresh, local food a durable part of household and community life.
Climate Resilience Depends on Community-Led Health Infrastructure
Marshall Hatch, Erik Mikaitis, Kareeshma Ali and Colleen Grogan argue that climate resilience in disinvested neighborhoods cannot be delivered through isolated cooling centers, clinics or green buildings. In West Garfield Park, they say, chronic disease, environmental exposure and limited access to care make climate risk a daily health problem, requiring locally led infrastructure, preventive investment and institutions willing to share power. Their case is for patient capital and durable partnerships that build on community trust rather than exporting short-term solutions.